Neoadjuvant QL1706 in Patients With Hormone Receptor Positive, HER2-negative Breast Cancer

Clinical trial NCT07396324 · RECRUITING

Trial details

NCT number: NCT07396324
Sponsor: RenJi Hospital
Status: RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

HR-positive/HER2-negative Breast Cancer

Start date: 2026-05-01
Primary completion: 2026-12-01
Enrollment: 55

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.